Is there a role for the no observed adverse effect level in safety pharmacology? [0.03%]
无不良反应水平在安全药理学中起作用吗？
Tomas Mow,Ninette K Andersen,Nils Dragsted et al.
Tomas Mow et al.
In nonclinical toxicology the highest dose or exposure without test article-related adverse effects, known as the No Observed Adverse Effect Level (NOAEL), is a variable that may be determined. In safety pharmacology the vast majority of th...
In vitro model using cytokine cocktail to evaluate apoptosis in Min6 pancreatic beta cells [0.03%]
使用细胞因子鸡尾酒的体外模型来评估Min6胰腺β细胞中的凋亡
Hemangee H Damame,Sheetalnath B Rooge,Rahul S Patil et al.
Hemangee H Damame et al.
Introduction: Development of therapy options for treatment of type 1 diabetes mellitus is hampered by non-availability of appropriate experimental models that can exactly mimic the in vivo situation. Apoptosis of beta cel...
Establishment of drug screening in human embryonic stem cells based on a high-content screening system [0.03%]
基于高内涵筛选系统的人胚胎干细胞药物筛选模型的建立
Yunfen Hua,Yongqin Wu,Xing Chun et al.
Yunfen Hua et al.
High-content screening (HCS) systems can be used for high-throughput screening of drugs in human embryonic stem cells (hESCs). However, hESCs require immunofluorescence staining with stemness markers (e.g., Oct-4) prior to HCS, which can be...
Schiefer counter: An alternative method for clonogenic assay evaluation [0.03%]
石板计数器：克隆形成实验评估的一种替代方法
A F Santos,E M Schiefer,M C Atherino et al.
A F Santos et al.
Introduction: Clonogenic assay evaluates the potential of cells to undergo division or generate clones following treatment with a chemical or other agent, thereby allowing the evaluation of cytotoxic and/or antiproliferat...
Twenty years of safety pharmacology model validation and the wider implications of this to drug discovery [0.03%]
二十年的安全药理学模型验证及其对药物发现的更广泛影响
Michael K Pugsley,Bisrat Bekele,Helene Griessel et al.
Michael K Pugsley et al.
This editorial summarizes the content of the current themed issue of J Pharm Tox Methods derived from the 2019 Annual Safety Pharmacology Society (SPS) meeting held in Barcelona, Spain, and reflects on 20 years of innovation in the elaborat...
Evaluation of urinary biomarkers for early detection of acute kidney injury in a rat nephropathy model [0.03%]
在大鼠肾病模型中对用于急性肾损伤早期检测的尿生物标志物进行评估
Kristina Kohl,Eva Herzog,Gerhard Dickneite et al.
Kristina Kohl et al.
Introduction: The implementation of novel, reliable biomarkers for the early and differential diagnosis of acute kidney injury (AKI) could greatly improve the timely treatment and prevention of disease progression, partic...
Revisiting the hERG safety margin after 20 years of routine hERG screening [0.03%]
二十年的常规hERG筛选后的安全边际重新评估
Derek J Leishman,Matthew M Abernathy,Evan B Wang
Derek J Leishman
Introduction: It has been two decades since screening new molecules and potential clinical drug candidates against the hERG potassium channel became a routine part of safety pharmacology. The earliest heuristic for what w...
James C Felli,Derek J Leishman
James C Felli
Introduction: Testing for toxicities is an important activity in drug development. In an ideal world the tests applied would be definitive. In reality this is seldom the case. There are two types of power associated with ...
Translation of in vitro cannabinoid 1 receptor agonist activity to in vivo pharmacodynamic endpoints [0.03%]
由体内大麻素1型受体激动剂活性向体内的药理学动态指标转化的译释研究
Stephen Jenkinson,Susan M G Goody,Asser Bassyouni et al.
Stephen Jenkinson et al.
Introduction: Building an understanding of in vivo efficacy based on the evaluation of in vitro affinity or potency is critical in expediting early decision making in drug discovery and can significantly reduce the need f...
Echocardiographic and hemodynamic indices of myocardial contractility simultaneously evaluated in telemetered beagle dogs: A HESI-sponsored cross-company evaluation [0.03%]
同步评价 telemetry 犬心肌收缩力的超声心动图及血流动力学指标：健康与环境科学研究所资助的跨公司评估项目
Eric I Rossman,Frank Cools,Jason Cordes et al.
Eric I Rossman et al.
Introduction: Alterations in cardiac contractility can have significant clinical implications, highlighting the need for early detection of potential liabilities. Pre-clinical methods to assess contractility are typically...